In the News
No differences found in effects of secondary diabetes drugs on kidney outcomes
A trial found similar rates of progression to kidney disease among patients with type 2 diabetes who were randomized to add a sulfonylurea, a dipeptidyl peptidase-4 inhibitor, a glucagon-like peptide-1 receptor agonist, or basal insulin to metformin treatment.
Afternoon physical activity linked to greater HbA1c reduction than other times of day
A secondary analysis of the Look AHEAD (Action for Health in Diabetes) study found that participants who performed more moderate to vigorous physical activity in the afternoon versus other times of day had the greatest reduction in HbA1c compared to those who were inactive.
EHR-based tool may help predict life expectancy in older patients with diabetes
The tool uses sex, body mass index, serum creatinine level, dementia, metastatic cancer, peripheral vascular disease, albuminuria, home oxygen use, wheelchair use, current smoking, and the interaction between age and heart failure to generate a risk score.
MKSAP quiz: Treatment for obesity
This month's quiz asks readers to evaluate a 48-year-old man during a follow-up visit for obesity. He has been unsuccessful in losing weight with diet. Medical history is significant for type 2 diabetes, hypertension, obstructive sleep apnea, and osteoarthritis.
Spotlight on racial differences in risk assessment
A scientific statement from the American Heart Association offered guidance on the epidemiology of diabetes among Asian American people, while an analysis of the algorithms for predicting type 2 diabetes found that they make lower estimates of risk in Black patients than White.
Pearls on diabetes meds in perioperative care
Learn when to stop and start glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
Bionic pancreas cleared for patients with type 1 diabetes
The new automated insulin dosing system, called the iLet Bionic Pancreas, is intended for use in patients ages 6 years and older with type 1 diabetes.